drugset / Trial / NCT06687928
To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)
RandomizedParallel-groupTriple-blindTreatment
Summary
A Randomized, Double-blind, Two-arm, Parallel-group, Single-dose, Phase 1 Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects
Timeline
- Start
- 2025-03-26
- Primary completion
- 2025-08-05
- Completion
- 2025-08-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Trastuzumab | Monoclonal antibody | 600 mg | Subcutaneous |
Indications
No indication recorded.